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aria Bianchi Janetti, MD,* Maria G. Signorini, PHD,‡ Paolo Castiglioni, PHD, Arianna Azzellino, PHD,§
iuseppe Mancia, MD,* Alberto U. Ferrari, MD*†
ilan and Monza, Italy
OBJECTIVES The intention of this study was to test the hypothesis that, in heart failure patients, dietary
supplementation of polyunsaturated fatty acids (PUFA) enhances arterial baroreceptor
control of the cardiovascular system.
BACKGROUND Administration of PUFA reduces the risk of life-threatening arrhythmias in patients surviving
myocardial infarction. This might result from potentiation of arterial baroreflexes, but
whether or not PUFA enhance baroreflex function has never been studied in humans.
METHODS Patients with post-myocardial infarction left ventricular dysfunction underwent beat-to-beat
blood pressure (BP) (Finapres, Ohmeda Inc., Englewood, Colorado) and R-R interval
(electrocardiogram) recording; baroreceptor reflexes were assessed from the bradycardic and
depressor responses to graded neck suction (NS) as well as by computation of the alpha
“spontaneous” baroreflex sensitivity index. Assessments were repeated after prolonged
treatment with PUFA (2 g/die, n  15) or placebo (n  10).
RESULTS Baseline BP and R-R interval were unaffected by PUFA. Both reflex depressor and
bradycardic responses to NS increased after PUFA (respectively from0.09 0.01 to0.16
 0.01 mm Hg · mm Hg1, p  0.01, and from 1.25  0.9 to 1.76  1.1 ms · mm Hg1,
p 0.04) but not after placebo. The spontaneous baroreflex sensitivity increased in the PUFA
(from 8.99  1.4 to 12.2  1.2 ms · mm Hg1, p  0.02) but not in the placebo group.
Polyunsaturated fatty acids (but not placebo) treatment also significantly increased R-R
interval total variance and low-frequency and high-frequency spectral powers.
CONCLUSIONS Dietary PUFA supplementation markedly potentiates baroreflex function and enhances heart
rate variability in patients with stable congestive heart failure. (J Am Coll Cardiol 2006;48:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.05.0731600–6) © 2006 by the American College of Cardiology Foundation
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oietary supplementation of N-3 polyunsaturated fatty acids
PUFA) has been shown to reduce the risk of life-
hreatening arrhythmias in post-myocardial infarction
post-MI) patients (1–4). However, the mechanisms un-
erlying such beneficial effect have not been completely
larified. In particular, although PUFA have been shown to
See page 1607
ave direct cardiac effects (5,6), which may play a role in
heir antiarrhythmic action (e.g., reduction of ventricular
utomaticity and prolongation of effective refractory pe-
iod), no evidence exists whether they can also favorably
odulate reflex cardiovascular control, whose derangement
From the *Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie
anitarie, Centro Interuniversitario di Fisiologia Clinica e Ipertensione, Università di
ilano-Bicocca, Milan, Italy; †Divisione di Riabilitazione Cardiologica, Ospedale
an Gerardo, Monza, Italy; the ‡Dipartimento di Bioingegneria and the §Diparti-
ento di Ingegneria Ambientale, Politecnico di Milano, Milan, Italy; and Centro di
ioingegneria, Fondazione Don Gnocchi, Milan, Italy. Kits for measurement of EPA
nd DHA plasma concentrations were supplied by Società Prodotti Antibiotici
Milan).i
Manuscript received March 10, 2006; revised manuscript received May 9, 2006,
ccepted May 22, 2006.as shown to significantly contribute to the high sudden
eath rate that characterizes the heart failure patient (7).
We therefore set up the present study to test the
ossibility that in post-MI, clinically stable, mild-to-
oderate congestive heart failure patients’ dietary PUFA
upplementation enhances the control exerted by arterial
aroreceptors on the cardiovascular system.
The assessment was based on a 2-fold technical approach:
) measurement of the bradycardic and depressor responses
o selective carotid baroreceptor stimulation by the neck
uction technique (8,9); 2) computation of the so-called
spontaneous” baroreceptor control of heart rate by cross-
pectral analysis of prolonged beat-to-beat blood pressure
ecordings (10).
ETHODS
tudy population. Twenty-five patients (24 men, 1
oman) with chronic post-MI systolic heart failure (ejec-
ion fraction lower than 40%) were recruited. In order to
void that the comparison of baroreflex responses on versus
ff PUFA supplementation be confounded by modifications
n the patient’s clinical status in terms of hemodynamic
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October 17, 2006:1600–6 Fish Oil and Arterial Baroreflexesompensation or drug regimen, we restricted recruitment to
linically stable subjects on optimized drug treatment with
eta-blockers, angiotensin-converting enzyme inhibitors,
nd diuretics. Twenty-three patients were also receiving
tatins. Administration of the above as well as of any other
ngoing drug was kept unmodified throughout the study.
xclusion criteria were clinical instability, recent (3
onths) changes in drug regimen, evidence of (inducible)
yocardial ischemia, sustained atrial or ventricular arrhyth-
ias, chronic obstructive pulmonary disease, diabetes mel-
itus, or any other major system disease. All patients were
urrent non-smokers. The protocol was approved by our
ocal ethical review board. All patients gave written consent
o participate in the study after being informed about its
ature and purpose. Patient characteristics including infor-
ation on ongoing drug treatment are shown in Table 1.
rotocol and data collection. In order to exclude hemo-
ynamic instability, each patient underwent a clinical exam-
nation that included history and physical examination with
etermination of the New York Heart Association (NYHA)
eart failure functional class, 12-lead electrocardiogram
ECG), a symptom-limited cardiorespiratory exercise test
ergospirometer model CPX/D, Medical Graphics Italy,
ilan, Italy), and a complete echocardiographic evaluation.
Patients were then randomly allocated to treatment for 4
onths with PUFA (2 g/day) or with placebo. Polyunsat-
rated fatty acids were manufactured as soft capsules with a
ontent of eicosapentaenoic (EPA) and docosahexaenoic
cid (DHA) of no less than 85% with an EPA/DHA ratio
f 0.9 to 1.5. Placebo capsules were provided by the hospital
harmaceutical service. Randomization was performed ac-
ording to a 3:2 (PUFA/placebo) criterion. The sample size
as calculated in order to disclose a 30% to 40% PUFA-
elated increase in baroreflex sensitivity.
able 1. General Clinical Characteristics of Actively and
lacebo-Treated Patient Groups
Placebo (n  10) PUFA (n  15)
ge (yrs) 60.1  2.7 59.4  2.5
O2 peak (ml/kg/min) 18.0  2.08 16.8  1.1
CE inhibitors 9/10 14/15
eta-blockers 9/10 14/15
tatins 9/10 14/15
iuretics 4/10 9/15
ntries preceding and following  denote mean and SEM.
Abbreviations and Acronyms
DHA  docosahexaenoic acid
EPA  eicosapentaenoic acid
HF  high frequency
LF  low frequency
NYHA  New York Heart Association
post-MI  post-myocardial infarction
PUFA  polyunsaturated fatty acidss
ACE  angiotensin-converting enzyme; PUFA  polyunsaturated fatty acids;
O2  volume of oxygen.No attempt was made to blind actively treated patients to
he taste of PUFA. However, patients were unaware of the
aste issue, in that they did not expect to experience any
pecial taste on taking the study pills; thus placebo-treated
atients had no elements to suspect that the pills they were
aking were pharmacologically inactive.
At the end of the study, blood was drawn to determine
igh sensitivity C-reactive protein (immunonephelometric
ethod) and plasma concentrations of PFAs, EPA, and
HA (gas chromatography).
Before and during the final week of randomized treat-
ent, each patient underwent a laboratory study for the
valuation of the arterial baroreflex and of cardiovascular
ariability. Each participant was asked to refrain from
rinking coffee and tea in the 24 h preceding the experi-
ental session. All recordings were performed in the early
fternoon in a quiet room with a temperature between 20°C
nd 23°C. The patient lay supine throughout. Recorded
ignals included: pulsatile finger blood pressure by Finapres
Ohmeda Inc., Englewood, Colorado), ECG and ventila-
ory activity by a custom-made thoracic impedance device.
ignals were fed through an analog-to-digital converter into
personal computer at a sampling rate of 500 Hz, visualized
hroughout on the computer screen, acquired and stored in
he computer memory during the periods of interest (see the
ollowing text). The neck suction stimulus was applied by
eans of a pneumatic chamber fitted around the individual’s
eck and connected to a commercial vacuum cleaner
dapted with a user-controlled leak to obtain the desired
egree of suction, monitored via a Statham pressure trans-
ucer (Ametek Power Instruments, Rochester, New York).
he study started after 5 to 10 min of quiet resting. It
onsisted of 4 separate and randomly sequenced experimen-
al periods, as follows: period 1: 10-min recording under
esting conditions and spontaneous breathing; period 2:
0-min recording under resting conditions and controlled
espiration at 15 cycles/min; period 3: 5-min recording
nder spontaneous breathing during which 2 neck suction
timuli were applied. The first stimulus consisted of a 30-s
eck suction at 20 mm Hg after a 120-s control pre-
timulus period. The second stimulus consisted of a 30-s
eck suction at 40 mm Hg after a 60-s pre-stimulus
eriod; period 4: same recordings and procedures as period
. A recovery interval lasting 3 to 5 min was allowed after
ach experimental period. Univariate and bivariate spectral
nalysis was only computed on the data colleted during period
, to avoid excess non-stationarities in the analyzed signals.
ata analysis. Systolic and diastolic blood pressure, mean
rterial pressure, and R-R interval were derived beat-by-
eat from the recorded blood pressure and ECG signals.
AROTID SINUS BARORECEPTOR STIMULATION. The peak
radycardic and depressor responses observed within 15 s of
he onset of neck suction were calculated as the average
alue of the 2 consecutive beats showing the greatest and
mallest value of R-R interval and mean arterial pressure,
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Fish Oil and Arterial Baroreflexes October 17, 2006:1600–6espectively. The regression of the peak reflex responses to
he graded negative neck chamber pressures was calculated,
he slope of the regression being taken as the measure of
aroreflex sensitivity. The magnitude of the observed re-
ponses in periods 3 and 4 were averaged.
NIVARIATE SPECTRAL ANALYSIS. A detailed description of
he spectral analysis technique used in this study has been
eported previously (11,12). In brief, time series of blood
ressure and pulse interval values obtained during controlled
reathing were analyzed by a parametric spectral estimation
ethod based on an autoregressive model. The method
llows the spectral power to be quantified in terms of central
requency (in Hz) and amplitude (in ms2 or mm Hg2) of the
ifferent variability components. Spectral powers of blood
ressure and R-R interval time series were calculated in
re-set bands, termed low frequency (LF) (0.04 to 0.15 Hz)
nd high frequency (HF) (0.15 to 0.50 Hz) bands (13).
IVARIATE CROSS-SPECTRAL ANALYSIS. The cross-spectral
nalysis used to calculate the spontaneous baroreflex sensi-
ivity has also been previously described (10). In brief, the
oherence between the changes in systolic blood pressure
nd R-R interval was calculated during controlled breathing
nd considered to be significant when the squared coherence
odulus was above 0.5 (11,12). The root-squared ratio
etween the spectral powers of coherent R-R interval and
ystolic blood pressure variations, called alpha index, which
uantifies the sensitivity of baroreflex control of heart rate
nder closed-loop conditions, was separately calculated for
he LF and HF bands (10).
tatistical comparisons. Statistical significance of the dif-
erences in baseline parameters and in alpha indexes after
ersus before treatment was assessed by the non-parametric
ilcoxon rank test.
Significance of the differences of the slopes calculated by
nalyzing the responses to the neck suction stimulus after
ersus before treatment was assessed by an analysis of
ovariance generalized linear model with a single-factor
epeated measures design. The factors considered by the
odel included: 1) a between subjects’ independent factor
Table 2. Mean Initial and Final Values of Eje
Interval, and R-R Interval Variability Paramet
Placeb
Initial
Ejection fraction (%) 36.6  2.5
Weight (kg) 77.9  4.5
NYHA functional class 2.44  0.3
SBP (mm Hg) 124  3
DBP (mm Hg) 81  3
R-R interval (ms) 954  37
R-R variance (ms2) 814  112
R-R–LF (ms2) 101  34
R-R–HF (ms2) 113  39
Entries are mean values  SEM. *p  0.05 final versus ini
DBP  diastolic blood pressure; HF  high frequency; LF  low
polyunsaturated fatty acids; SBP  systolic blood pressure.i.e., PUFA vs. placebo group); 2) a within subjects’ re-
eated factor (i.e., after vs. before treatment); and 3) a
ovariate (i.e., the neck suction stimulus) (14). Moreover,
e also tested whether the increments of slopes after versus
efore treatment were significantly different between the 2
roups (unpaired t test).
Significance of the changes in spectral powers after versus
efore treatment were evaluated by the paired t test after
ogarithmic transformation or by the Wilcoxon non-
arametric rank test as appropriate.
For each comparison, the level of statistical significance
as set at a value of p  0.05.
ESULTS
lood chemistry. At the final evaluation, the plasma con-
entrations of polyunsaturated acids were significantly
igher in the treated compared with the placebo group
placebo group: EPA 4.8  1.3, DHA 10.7  1.1
g · mg1 · l1; PUFA group: EPA 10.5  1.1, DHA
5.8 0.9 g · mg1 · l1, both p 0.01). High sensitivity
-reactive protein was similar in the 2 groups and was
naffected by PUFA treatment (placebo group: 2.6  1.5;
UFA group: 2.5  0.7 mg · l1, p  NS).
ardiovascular parameters. Echocardiographically deter-
ined left ventricular function as well as NYHA functional
lass and body weight were all unchanged at the final
ompared with the initial evaluation in both the PUFA- and
he placebo-treated groups (Table 2).
Baseline blood pressure was similar in the 2 groups and
as unaffected by either PUFA or placebo treatment.
aseline R-R interval was also similar in the 2 groups and
as unchanged after placebo treatment whereas after PUFA
reatment it showed a trend to a lengthening (amounting to
bout 60 to 70 ms or 4 to 5 beats/min), which, however, did
ot reach statistical significance (Table 2). In line with
revious findings, R-R interval variability, computed as
ither total variance or spectral power, was significantly and
arkedly enhanced after PUFA treatment, whereas it was
nchanged after placebo treatment (Table 2).
Fraction, Body Weight, Blood Pressure, R-R
PUFA
Final Initial Final
8  2.1 34.7  1.5 34.5  1.8
1  3.2 77.3  2.0 78.1  2.4
9  0.3 2.34  0.2 2.36  0.3
0  4 119  5 119  4
8  3 78  3 79  3
3  34 921  29 987  39
4  92 845  124 1,265  220*
6  39 50  21 190  51†
8  47 210  69 370  106*
aluation; †p  0.01 versus initial evaluation.ction
ers
o
35.
78.
2.3
12
7
95
81
9
13
tial ev
frequency; NYHA  New York Heart Association; PUFA 
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October 17, 2006:1600–6 Fish Oil and Arterial Baroreflexesesponses to carotid baroreceptor stimulation. As shown
n the examples of Figure 1, the bradycardic responses to
eck suction were larger after versus before PUFA treat-
ent, whereas they showed no consistent modifications
fter versus before placebo treatment (center panels); the
ame applied to the depressor responses to neck suction (top
anels). As shown in Figure 2, this pattern was confirmed in
he group analysis in which the average slopes of the
radycardic (or depressor) responses to neck suction were
ignificantly steeper after versus before PUFA treatment
p  0.005 for the R-R interval slopes and 0.00013 for
he mean arterial pressure slopes) but not after versus before
lacebo treatment. In fact, the change in the bradycardic
lopes was significantly greater in the PUFA- than in the
lacebo-treated group (0.51  0.16 vs. 0.11  0.26
s · mm Hg1, p  0.04), and the same was observed for
he depressor slopes (0.06  0.01 vs. 0.02  0.01 mm
g · mm Hg1, p  0.006).
Spontaneous” baroreceptor control of heart rate. As
hown in Figure 3, the alpha index (computed in either the
F or HF spectral band) was similar in the 2 groups at
aseline, whereas at the final evaluation its values were
ignificantly increased in the group treated with PUFA but
ere unchanged in the placebo-treated group.
ISCUSSION
ur study provides the first demonstration that a 4-month
ietary supplementation of polyunsaturated fatty acids is
igure 1. Carotid baroreceptor stimulation. Examples showing the effects o
eart rate (HR) (center) in a placebo- (left) and in a polyunsaturated fatty a
ote the modest responses to carotid baroreceptor stimulation observed in
esponses after 4 months of treatment with PUFA but not with placebo.ccompanied by a partial restoration of several indices of cardiovascular homeostatic control that are typically de-
ressed in the heart failure patient, namely: 1) baroreceptor
ontrol of heart rate; 2) baroreceptor control of the periph-
ral vasculature; and 3) heart rate variability. It also shows
hat the extent of the baroreflex improvement was far from
rivial: in the neck suction experiments, the calculated slopes
or the bradycardic and depressor responses were respec-
ively 40% and 75% steeper during PUFA treatment than
t baseline. This made the slopes only slightly less steep
n PUFA-treated heart failure patients compared with
ge-matched healthy patients studied by the same tech-
ique (14).
Before discussing the mechanisms underlying these re-
ults and their possible pathophysiological and clinical
mplications, some methodological strengths of our study
ave to be emphasized.
The most important one is that we assessed the baroreflex
y a 2-fold approach: 1) the neck suction technique (8,9),
hich allows one to grade the stimulus applied to carotid
aroreceptors and thus to characterize the baroreflex
timulus-response relationship both for the cardiac and the
lood pressure component of the baroreflex (15); 2) com-
utation of the alpha index, which cross-spectrally estimates
he ability of the baroreflex to modulate heart rate under
spontaneous” conditions (i.e., in absence of any laboratory
timuli) (10,11).
A second technical feature relates to inclusion in the
rotocol of blood pressure recordings sessions that were
k suction (NS) (40 mm Hg, bottom) on blood pressure (BP) (top), and
UFA)-treated (right) patient both before (pre) and after (post) treatment.
patients at the initial evaluation and the clearcut depressor and bradycardicf nec
cid (Ponducted during controlled breathing and were used to
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Fish Oil and Arterial Baroreflexes October 17, 2006:1600–6erform univariate and bivariate spectral analysis: the pur-
ose was to avoid a serious pitfall of frequency domain
echniques (i.e., the occurrence of erratic modifications of
ardiovascular variability related to episodes of irregular
reathing), which is a quite common event in heart failure
atients (16,17).
igure 2. R-R interval (top) and mean arterial blood pressure (bottom) r
upine individuals before (solid lines, circles) and after (dotted lines, tria
right) or placebo (left). Mean values  SEM of the responses to 20 m
he reflex response to the stimulus are shown. Slopes and correlation co
upplementation.
igure 3. Alpha baroreflex index before and after placebo (white bars) and
olyunsaturated fatty acid (PUFA) (shaded bars) treatment. Note that in
he PUFA-treated group the alpha index increased significantly both in thep
ow-frequency (LF) and high-frequency (HF) bands. **p  0.01 versus
aseline.Although addressing the mechanisms underlying PUFA-
nduced modifications of baroreflex function was not among
he goals of our study, our results prompt several consider-
tions on this issue. One, the baroreflex potentiation cannot
e aspecifically ascribed to a treatment-related attenuation
f the severity of heart failure, because the functional
chocardiographic parameters as well as the patients’ clinical
tatus and NYHA functional class were superimposable at
aseline and after PUFA treatment. Two, the evidence that
he potentiation involved not only the heart rate but also the
lood pressure control exerted by arterial baroreceptors
uggests that the influence of PUFA involves both the vagal
which largely accounts for the reflex heart rate changes) and
he sympathetic component of the baroreflex and is there-
ore presumably expressed at sites located in the afferent
nd/or central portion of the reflex arch. We can speculate
hat afferent mechanisms may include an attenuation (18) of
he arterial stiffening brought about by heart failure (19),
lthough a direct effect of PUFA on baroreceptor firing in
esponse to physiological stimuli or on its central neural
ses to carotid baroreceptor stimulation by graded neck suction in resting
) 4 months of dietary polyunsaturated fatty acid (PUFA) supplementation
and 40 mm Hg neck suction and the derived regression lines relating
nts (r) are indicated for each regression line. **p  0.01 versus beforeespon
ngles
m Hgrocessing might also be involved (20–22). Three, wherever
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October 17, 2006:1600–6 Fish Oil and Arterial Baroreflexeshe site of the action of PUFA, the observation that serum
igh sensitive C-reactive protein concentration was super-
mposable in the actively and placebo-treated groups sug-
ests that no anti-inflammatory effect of PUFA was in-
olved. This is not surprising because C-reactive protein
evels were low even in the placebo-treated group, probably
ue to the fact that most recruited patients were under statin
reatment (Table 1), which by its own exerts an anti-
nflammatory influence (23).
Our results have clinical implications. One, our dietary
reatment ameliorated 3 parameters whose depression cor-
elates with an adverse prognosis in heart failure patients,
amely baroreflex sensitivity (7), overall heart rate variabil-
ty, and LF spectral power of R-R interval (24,25). Two,
estoration of the depressor responses to neck suction by
UFA may favorably affect cardiovascular homeostasis,
hich means better cardiovascular adjustments to exercise,
igestion, orthostatic stimuli, and other daily life behaviors.
hree, the favorable effect of PUFA on the baroreflex
ccurred in heart failure patients that were all under
reatment with both beta-blockers and angiotensin-
onverting enzyme inhibitors (i.e., with drugs that are
nown to potentiate the vagal and sympathetic components
f the baroreflex in heart failure) (26,27). This means that
he baroreflex effect of these substances is additive to that of
ther treatments. Four, the trend we observed to a reduction
n baseline heart rate with PUFA is in line with a recently
eported meta-analysis according to which these substances
re accompanied by a 2 to 3 beat/min reduction in heart rate
28); on the other hand, it is not surprising that we failed to
bserve any trend to a reduction in baseline blood pressure
ecause in virtually all patients the ongoing drug regimen
dministered for the treatment of heart failure was already
xerting a significant blood pressure–lowering influence.
Five, the PUFA-related changes in LF spectral power of
eart rate variability suggest that this treatment evoked an
ttenuation of sympathetic overactivity; this is because, at
ariance with healthy subjects, in heart failure patients
xaggerated sympathetic tone translates into blunted rather
han enhanced LF oscillations of heart rate (29). Likewise,
he PUFA-related increase in HF power likely reflects
estoration of the blunted cardiac parasympathetic influ-
nces. As to this interpretation, one might argue that
stimation of sympathetic function by a spectral approach is
nferential in nature and must be interpreted with caution,
nd that our baroreflex study tested the sympatho-inhibitory
ut not the sympatho-excitatory limb of the reflex; this
ould mean that, in all, our findings do not exclude that
hile able to moderate tonic sympathetic outflow and to
otentiate phasic sympatho-inhibitory responses, PUFA
reatment may fail to restrain or might even enhance phasic
ympatho-excitatory responses. No matter how likely it may
e, this possibility will merit direct experimental testing,
specially considering the provocative suggestion (30) that
UFA may not lower, or may even raise, the propensity to
entricular arrhythmias; it must at any rate be emphasized ohat this relates to patients with a primary arrhythmogenic
ubstrate and is unlikely to apply to the large population
f post-MI heart failure patients (31), such as our own or
hose in the GISSI Study (Gruppo Italiano per lo Studio
ella Sopravvivenza nell’Infarto miocardico acuto-1) (1),
n whom PUFA proved to be anti- rather than pro-
rrhythmic.
Our study also has some potential limitations. First, we
ould only determine fatty acid concentrations at the end of
he experimental treatment period. This was because we
ere supplied with a limited number of plasma sampling
its, which made it impossible for us to sample both pre-
nd post-treatment, as well as to perform determinations
ther than in plasma (e.g., in red cell membranes). It is
owever to be considered that: 1) we collected dietary
nformation in all patients; in particular, we ascertained that
one of the recruited patients ate seafood more often than
nce a week (which is quite normal for Northern Italian
ietary habits), whereas the 2 g daily dosage administered to
he PUFA group subjects determines an intake of PUFA
orresponding to that of individuals eating large amounts of
eafood (at least 200 g of fatty fish per day); 2) compared
ith the placebo-treated subjects, the PUFA-treated ones
isplayed plasma PUFA concentrations 100% and 50%
arger for EPA and DHA, respectively. We can thus most
easonably exclude that the observed differences in plasma
oncentrations of PUFA between the 2 groups were pre-
xistent to our randomized treatment, so that this issue
hould not have acted as a confounder in the interpretation
f the baroreflex findings.
Second, although PUFA treatment enhanced patients’
aroreflex function, this was not paralleled by significant
mprovements in clinical status as inferred by body weight,
YHA functional class, and echocardiographic parameters.
lthough they should be interpreted with caution because
f the limited size of our population, these clinical data
uggest that in the heart failure syndrome PUFA admin-
stration has little symptomatic relevance. This does not
etract, however, from the clinical relevance of the
aroreflex potentiation, which one would expect to have
ore bearing with a reduction in the risk of sudden and
ll-cause death than with an improvement in the symp-
omatic picture.
In conclusion, we demonstrated that administration to
eart failure patients of a diet enriched in PUFAs is
ssociated with a substantial improvement of arterial barore-
ex function (in terms of both cardiac and peripheral
ascular control) and of heart rate variability (total variance
s well as power of its spectral components). Notably,
lterations in most of the cardiovascular homeostatic
arameters examined in our experiments are known to
redict an adverse prognosis in the heart failure patient,
nd PUFA treatment proved to be able to improve each
f them.
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